AAPL349.51+17.61 (+5.31%) ▲|ABBV294.83+8.83 (+3.09%) ▲|ABT115.51+6.11 (+5.59%) ▲|ACN264.27+9.71 (+3.81%) ▲|ADBE248.48+2.34 (+0.95%) ▲|AMAT369.40-12.52 (-3.28%) ▼|AMD488.78+4.88 (+1.01%) ▲|AMGN478.48+17.22 (+3.73%) ▲|AMT194.86+7.57 (+4.04%) ▲|AMZN266.03+15.34 (+6.12%) ▲|AVGO325.48-6.65 (-2.00%) ▼|AXP332.59+7.09 (+2.18%) ▲|BA177.00+3.69 (+2.13%) ▲|BAC51.63+1.97 (+3.97%) ▲|BKNG170.97+15.30 (+9.83%) ▲|BLK1,224.37+63.05 (+5.43%) ▲|BMY64.19+2.48 (+4.02%) ▲|BNY152.72+3.41 (+2.28%) ▲|BRK-B579.09+22.02 (+3.95%) ▲|C124.74+2.03 (+1.65%) ▲|CAT591.30-32.64 (-5.23%) ▼|CL98.76+3.14 (+3.28%) ▲|CMCSA24.85+1.18 (+4.99%) ▲|COF206.31-2.40 (-1.15%) ▼|COP136.94-7.46 (-5.17%) ▼|COST1,046.47+27.21 (+2.67%) ▲|CRM227.11+4.91 (+2.21%) ▲|CSCO103.61+0.64 (+0.62%) ▲|CVS79.96-11.45 (-12.53%) ▼|CVX216.96-8.31 (-3.69%) ▼|DE676.50+10.67 (+1.60%) ▲|DHR234.93+4.82 (+2.09%) ▲|DIS118.95+4.77 (+4.18%) ▲|DUK129.59+3.08 (+2.43%) ▲|EMR170.44+4.05 (+2.43%) ▲|FDX329.40+11.38 (+3.58%) ▲|GD364.87-9.63 (-2.57%) ▼|GE329.45+8.78 (+2.74%) ▲|GEV832.83-85.37 (-9.30%) ▼|GILD174.48+7.01 (+4.19%) ▲|GM92.43+4.09 (+4.63%) ▲|GOOG287.30+9.03 (+3.25%) ▲|GOOGL288.93+8.90 (+3.18%) ▲|GS928.00+31.91 (+3.56%) ▲|HD355.44+21.78 (+6.53%) ▲|HON228.47+4.42 (+1.97%) ▲|IBM254.32+4.28 (+1.71%) ▲|INTC58.27-2.28 (-3.77%) ▼|INTU356.64+11.92 (+3.46%) ▲|ISRG482.10+41.35 (+9.38%) ▲|JNJ276.32+10.15 (+3.81%) ▲|JPM352.11+14.13 (+4.18%) ▲|KO95.80+1.00 (+1.05%) ▲|LIN524.74+13.19 (+2.58%) ▲|LLY1,417.99+8.61 (+0.61%) ▲|LMT595.04-43.96 (-6.88%) ▼|LOW229.38+16.00 (+7.50%) ▲|LRCX221.43-9.29 (-4.03%) ▼|MA672.68+25.50 (+3.94%) ▲|MCD280.22+17.18 (+6.53%) ▲|MDLZ67.38+2.26 (+3.47%) ▲|MDT104.96+6.08 (+6.15%) ▲|META630.00+8.97 (+1.44%) ▲|MMM193.95+16.90 (+9.55%) ▲|MO78.01+1.07 (+1.39%) ▲|MRK150.36+5.69 (+3.93%) ▲|MS193.97+7.88 (+4.23%) ▲|MSFT555.80+34.81 (+6.68%) ▲|MU795.23-59.87 (-7.00%) ▼|NEE88.45+4.12 (+4.89%) ▲|NFLX66.39+2.97 (+4.68%) ▲|NKE40.49+2.01 (+5.22%) ▲|NOW108.81-0.35 (-0.32%) ▼|NVDA200.13-6.56 (-3.17%) ▼|ORCL123.73-2.46 (-1.95%) ▼|PEP142.42+5.15 (+3.75%) ▲|PFE30.79+0.79 (+2.63%) ▲|PG167.32+5.26 (+3.25%) ▲|PLTR171.70-3.70 (-2.11%) ▼|PM211.28+3.25 (+1.56%) ▲|QCOM173.19+8.76 (+5.33%) ▲|RTX198.43-5.39 (-2.64%) ▼|SBUX109.70+4.93 (+4.71%) ▲|SCHW93.37+4.09 (+4.58%) ▲|SO93.12-0.63 (-0.67%) ▼|SPG228.50+6.42 (+2.89%) ▲|T21.83+0.44 (+2.06%) ▲|TMO706.16+7.82 (+1.12%) ▲|TMUS159.17+4.76 (+3.08%) ▲|TSLA385.19-13.31 (-3.34%) ▼|TXN311.49-1.00 (-0.32%) ▼|UBER69.87+3.27 (+4.91%) ▲|UNH409.38+4.94 (+1.22%) ▲|UNP308.53+5.10 (+1.68%) ▲|UPS114.31+5.14 (+4.71%) ▲|USB61.03+1.14 (+1.90%) ▲|V436.57+16.15 (+3.84%) ▲|VZ46.17+0.93 (+2.06%) ▲|WFC87.43+1.90 (+2.22%) ▲|WMT129.17+4.31 (+3.45%) ▲|XOM169.27-8.19 (-4.62%) ▼|AAPL349.51+17.61 (+5.31%) ▲|ABBV294.83+8.83 (+3.09%) ▲|ABT115.51+6.11 (+5.59%) ▲|ACN264.27+9.71 (+3.81%) ▲|ADBE248.48+2.34 (+0.95%) ▲|AMAT369.40-12.52 (-3.28%) ▼|AMD488.78+4.88 (+1.01%) ▲|AMGN478.48+17.22 (+3.73%) ▲|AMT194.86+7.57 (+4.04%) ▲|AMZN266.03+15.34 (+6.12%) ▲|AVGO325.48-6.65 (-2.00%) ▼|AXP332.59+7.09 (+2.18%) ▲|BA177.00+3.69 (+2.13%) ▲|BAC51.63+1.97 (+3.97%) ▲|BKNG170.97+15.30 (+9.83%) ▲|BLK1,224.37+63.05 (+5.43%) ▲|BMY64.19+2.48 (+4.02%) ▲|BNY152.72+3.41 (+2.28%) ▲|BRK-B579.09+22.02 (+3.95%) ▲|C124.74+2.03 (+1.65%) ▲|CAT591.30-32.64 (-5.23%) ▼|CL98.76+3.14 (+3.28%) ▲|CMCSA24.85+1.18 (+4.99%) ▲|COF206.31-2.40 (-1.15%) ▼|COP136.94-7.46 (-5.17%) ▼|COST1,046.47+27.21 (+2.67%) ▲|CRM227.11+4.91 (+2.21%) ▲|CSCO103.61+0.64 (+0.62%) ▲|CVS79.96-11.45 (-12.53%) ▼|CVX216.96-8.31 (-3.69%) ▼|DE676.50+10.67 (+1.60%) ▲|DHR234.93+4.82 (+2.09%) ▲|DIS118.95+4.77 (+4.18%) ▲|DUK129.59+3.08 (+2.43%) ▲|EMR170.44+4.05 (+2.43%) ▲|FDX329.40+11.38 (+3.58%) ▲|GD364.87-9.63 (-2.57%) ▼|GE329.45+8.78 (+2.74%) ▲|GEV832.83-85.37 (-9.30%) ▼|GILD174.48+7.01 (+4.19%) ▲|GM92.43+4.09 (+4.63%) ▲|GOOG287.30+9.03 (+3.25%) ▲|GOOGL288.93+8.90 (+3.18%) ▲|GS928.00+31.91 (+3.56%) ▲|HD355.44+21.78 (+6.53%) ▲|HON228.47+4.42 (+1.97%) ▲|IBM254.32+4.28 (+1.71%) ▲|INTC58.27-2.28 (-3.77%) ▼|INTU356.64+11.92 (+3.46%) ▲|ISRG482.10+41.35 (+9.38%) ▲|JNJ276.32+10.15 (+3.81%) ▲|JPM352.11+14.13 (+4.18%) ▲|KO95.80+1.00 (+1.05%) ▲|LIN524.74+13.19 (+2.58%) ▲|LLY1,417.99+8.61 (+0.61%) ▲|LMT595.04-43.96 (-6.88%) ▼|LOW229.38+16.00 (+7.50%) ▲|LRCX221.43-9.29 (-4.03%) ▼|MA672.68+25.50 (+3.94%) ▲|MCD280.22+17.18 (+6.53%) ▲|MDLZ67.38+2.26 (+3.47%) ▲|MDT104.96+6.08 (+6.15%) ▲|META630.00+8.97 (+1.44%) ▲|MMM193.95+16.90 (+9.55%) ▲|MO78.01+1.07 (+1.39%) ▲|MRK150.36+5.69 (+3.93%) ▲|MS193.97+7.88 (+4.23%) ▲|MSFT555.80+34.81 (+6.68%) ▲|MU795.23-59.87 (-7.00%) ▼|NEE88.45+4.12 (+4.89%) ▲|NFLX66.39+2.97 (+4.68%) ▲|NKE40.49+2.01 (+5.22%) ▲|NOW108.81-0.35 (-0.32%) ▼|NVDA200.13-6.56 (-3.17%) ▼|ORCL123.73-2.46 (-1.95%) ▼|PEP142.42+5.15 (+3.75%) ▲|PFE30.79+0.79 (+2.63%) ▲|PG167.32+5.26 (+3.25%) ▲|PLTR171.70-3.70 (-2.11%) ▼|PM211.28+3.25 (+1.56%) ▲|QCOM173.19+8.76 (+5.33%) ▲|RTX198.43-5.39 (-2.64%) ▼|SBUX109.70+4.93 (+4.71%) ▲|SCHW93.37+4.09 (+4.58%) ▲|SO93.12-0.63 (-0.67%) ▼|SPG228.50+6.42 (+2.89%) ▲|T21.83+0.44 (+2.06%) ▲|TMO706.16+7.82 (+1.12%) ▲|TMUS159.17+4.76 (+3.08%) ▲|TSLA385.19-13.31 (-3.34%) ▼|TXN311.49-1.00 (-0.32%) ▼|UBER69.87+3.27 (+4.91%) ▲|UNH409.38+4.94 (+1.22%) ▲|UNP308.53+5.10 (+1.68%) ▲|UPS114.31+5.14 (+4.71%) ▲|USB61.03+1.14 (+1.90%) ▲|V436.57+16.15 (+3.84%) ▲|VZ46.17+0.93 (+2.06%) ▲|WFC87.43+1.90 (+2.22%) ▲|WMT129.17+4.31 (+3.45%) ▲|XOM169.27-8.19 (-4.62%) ▼|
17 C
New York
Thursday, November 5, 2026

Tag: years

newsFORsourcecompanycontentinformationreleases1market

Aaron Fraser Marks 5 Years of The Action Sports Club with #1 International Best-Selling Sponsorship Guide

The Modern Playbook for Sponsorship and Cash Flow helps athletes get sponsored, grow their brand, and turn passion into profit. Kelowna, BC, Aug. 9, 2025...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inspire Medical Systems, Inc. – INSP

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Groupon, Inc. – GRPN

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Groupon, Inc. (“Groupon” or the “Company”) (NASDAQ: GRPN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of agilon health, Inc. – AGL

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  agilon health, Inc. (“agilon” or the “Company”) (NYSE: AGL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. – ALT

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Altimmune, Inc.  (“Altimmune” or the “Company”) (NASDAQ: ALT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Designer Brands Inc. – DBI

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Designer Brands Inc.  (“Designer Brands” or the “Company”) (NYSE: DBI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. – UNCY

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE – ARGX

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. – DYN

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. – EWTX

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KBR, Inc. – KBR

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of KBR, Inc.  (“KBR” or the “Company”) (NYSE: KBR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of American Outdoor Brands, Inc. – AOUT

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  American Outdoor Brands, Inc. (“American Outdoor” or the “Company”) (NASDAQ: AOUT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

KeySlim Drops Explores Ingredient-First Weight Management Trends in 2025

A Science-Backed Look at How KeySlim Drops’ Natural Formula Aligns With Evolving Healthy Weight Goals 
A Science-Backed Look at How KeySlim Drops’ Natural Formula Aligns With Evolving Healthy Weight Goals

GLP-1 Plus by Advanced BioNutritionals: 2025 DHB Breakthrough Ignites Interest in Non-Injection Hunger and Weight Trends

GLP-1 Plus by Advanced BioNutritionals enters the spotlight with a patented dihydroberberine (DHB) formula in 2025, reflecting rising interest in GLP-1 alternatives and non-injection hunger support solutions. 
GLP-1 Plus by Advanced BioNutritionals enters the spotlight with a patented dihydroberberine (DHB) formula in 2025, reflecting rising interest in GLP-1 alternatives and non-injection hunger support solutions.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsYears

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers